[{"@context":"http:\/\/schema.org\/","@type":"BlogPosting","@id":"https:\/\/wiki.edu.vn\/en\/wiki24\/2015\/03\/02\/gw0742-wikipedia\/#BlogPosting","mainEntityOfPage":"https:\/\/wiki.edu.vn\/en\/wiki24\/2015\/03\/02\/gw0742-wikipedia\/","headline":"GW0742 – Wikipedia","name":"GW0742 – Wikipedia","description":"From Wikipedia, the free encyclopedia PPAR \u03b2\/\u03b4 receptor Agonist compound GW0742 (also known as GW610742) is a PPAR\u03b4\/\u03b2 agonist[2][3][4] that","datePublished":"2015-03-02","dateModified":"2015-03-02","author":{"@type":"Person","@id":"https:\/\/wiki.edu.vn\/en\/wiki24\/author\/lordneo\/#Person","name":"lordneo","url":"https:\/\/wiki.edu.vn\/en\/wiki24\/author\/lordneo\/","image":{"@type":"ImageObject","@id":"https:\/\/secure.gravatar.com\/avatar\/c9645c498c9701c88b89b8537773dd7c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c9645c498c9701c88b89b8537773dd7c?s=96&d=mm&r=g","height":96,"width":96}},"publisher":{"@type":"Organization","name":"Enzyklop\u00e4die","logo":{"@type":"ImageObject","@id":"https:\/\/wiki.edu.vn\/wiki4\/wp-content\/uploads\/2023\/08\/download.jpg","url":"https:\/\/wiki.edu.vn\/wiki4\/wp-content\/uploads\/2023\/08\/download.jpg","width":600,"height":60}},"image":{"@type":"ImageObject","@id":"https:\/\/en.wikipedia.org\/wiki\/Special:CentralAutoLogin\/start?type=1x1","url":"https:\/\/en.wikipedia.org\/wiki\/Special:CentralAutoLogin\/start?type=1x1","height":"1","width":"1"},"url":"https:\/\/wiki.edu.vn\/en\/wiki24\/2015\/03\/02\/gw0742-wikipedia\/","about":["Wiki"],"wordCount":4185,"articleBody":"From Wikipedia, the free encyclopediaPPAR \u03b2\/\u03b4 receptor Agonist compoundGW0742 (also known as GW610742) is a PPAR\u03b4\/\u03b2 agonist[2][3][4] that is investigated for drug use by GlaxoSmithKline.[5]Pharmacology[edit]Pharmacodynamics[edit]It is mixed PPAR-B agonist antagonist depending on its dosage.[6] It has weak activity on multiple nuclear receptors as well. It is antagonistic at androgen receptors and VDR.[6][7] In silico modelling suggest that it has effects on thyroid hormone receptors.[8]Chemistry[edit]Derivatives[edit]Multiple derivatives of GW0742 core structure has been developed. One of the compound, which has thiazole ring replaced with an oxazole ring inhibited VDR-meditated transcription with IC50 of 660 nM.[7] Other novel analogues which are more potent than GWO742 with reduced toxicity has been developed as well.[9]Research[edit]GW0742 has been shown to ameliorate experimentally induced pancreatitis in mice.[10] It also prevents hypertension in diet induced obese mice.[11] and is investigated as potential antidiabetic drug as well.[12] It is anti-inflammatory agent as well.[13][14][11]See also[edit]References[edit]^ “Cayman Chemical GW0742”. Retrieved 31 Mar 2013.^ Smith SA, Monteith GR, Robinson JA, Venkata NG, May FJ, Roberts-Thomson SJ (July 2004). “Effect of the peroxisome proliferator-activated receptor beta activator GW0742 in rat cultured cerebellar granule neurons”. Journal of Neuroscience Research. 77 (2): 240\u20139. doi:10.1002\/jnr.20153. PMID\u00a015211590. S2CID\u00a021295375.^ Haskova Z, Hoang B, Luo G, Morgan LA, Billin AN, Barone FC,  et\u00a0al. (July 2008). “Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPARbeta\/delta ligand GW0742”. Inflammation Research. 57 (7): 314\u201321. doi:10.1007\/s00011-007-7157-4. PMID\u00a018622687. S2CID\u00a025631088.^ Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, Lambert MH, Willson TM, Oliver WR, Sternbach DD (May 2003). “Novel selective small molecule agonists for peroxisome proliferator-activated receptor \u03b4 (PPAR\u03b4)–synthesis and biological activity”. Bioorganic & Medicinal Chemistry Letters. 13 (9): 1517\u201321. doi:10.1016\/s0960-894x(03)00207-5. PMID\u00a012699745.^ Wagner N, Jehl-Pi\u00e9tri C, Lopez P, Murdaca J, Giordano C, Schwartz C,  et\u00a0al. (July 2009). “Peroxisome proliferator-activated receptor beta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin”. Cardiovascular Research. 83 (1): 61\u201371. doi:10.1093\/cvr\/cvp106. PMID\u00a019351742.^ a b Nandhikonda P, Yasgar A, Baranowski AM, Sidhu PS, McCallum MM, Pawlak AJ, Teske K, Feleke B, Yuan NY, Kevin C, Bikle DD, Ayers SD, Webb P, Rai G, Simeonov A, Jadhav A, Maloney D, Arnold LA (June 2013). “Peroxisome proliferation-activated receptor \u03b4 agonist GW0742 interacts weakly with multiple nuclear receptors, including the vitamin D receptor”. Biochemistry. 52 (24): 4193\u2013203. doi:10.1021\/bi400321p. PMC\u00a03724348. PMID\u00a023713684.^ a b Teske KA, Bogart JW, Arnold LA (February 2018). “Novel VDR antagonists based on the GW0742 scaffold”. Bioorganic & Medicinal Chemistry Letters. 28 (3): 351\u2013354. doi:10.1016\/j.bmcl.2017.12.041. PMC\u00a06008168. PMID\u00a029287957.^ Perez Diaz N, Zloh M, Patel P, Mackenzie LS (January 2016). “In silico modelling of prostacyclin and other lipid mediators to nuclear receptors reveal novel thyroid hormone receptor antagonist properties”. Prostaglandins & Other Lipid Mediators. 122: 18\u201327. doi:10.1016\/j.prostaglandins.2015.12.002. PMID\u00a026686607.^ Teske KA, Rai G, Nandhikonda P, Sidhu PS, Feleke B, Simeonov A, Yasgar A, Jadhav A, Maloney DJ, Arnold LA (October 2017). “Parallel Chemistry Approach to Identify Novel Nuclear Receptor Ligands Based on the GW0742 Scaffold”. ACS Combinatorial Science. 19 (10): 646\u2013656. doi:10.1021\/acscombsci.7b00066. PMC\u00a05643073. PMID\u00a028825467.^ Paterniti I, Mazzon E, Riccardi L, Galuppo M, Impellizzeri D, Esposito E, Bramanti P, Cappellani A, Cuzzocrea S (July 2012). “Peroxisome proliferator-activated receptor \u03b2\/\u03b4 agonist GW0742 ameliorates cerulein- and taurocholate-induced acute pancreatitis in mice”. Surgery. 152 (1): 90\u2013106. doi:10.1016\/j.surg.2012.02.004. PMID\u00a022521259.^ a b Toral M, G\u00f3mez-Guzm\u00e1n M, Jim\u00e9nez R, Romero M, Zarzuelo MJ, Utrilla MP, Hermenegildo C, Cogolludo \u00c1, P\u00e9rez-Vizca\u00edno F, G\u00e1lvez J, Duarte J (September 2015). “Chronic peroxisome proliferator-activated receptor\u03b2\/\u03b4 agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity”. Journal of Hypertension. 33 (9): 1831\u201344. doi:10.1097\/HJH.0000000000000634. PMID\u00a026147382. S2CID\u00a038565637.^ Niu HS, Ku PM, Niu CS, Cheng JT, Lee KS (2015). “Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals”. Drug Design, Development and Therapy. 9: 5625\u201332. doi:10.2147\/DDDT.S95045. PMC\u00a04610778. PMID\u00a026508837.^ Di Paola R, Esposito E, Mazzon E, Paterniti I, Galuppo M, Cuzzocrea S (August 2010). “GW0742, a selective PPAR-beta\/delta agonist, contributes to the resolution of inflammation after gut ischemia\/reperfusion injury”. Journal of Leukocyte Biology. 88 (2): 291\u2013301. doi:10.1189\/jlb.0110053. PMID\u00a020430778. S2CID\u00a021168990.^ Haskova Z, Hoang B, Luo G, Morgan LA, Billin AN, Barone FC, Shearer BG, Barton ME, Kilgore KS (July 2008). “Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPARbeta\/delta ligand GW0742”. Inflammation Research. 57 (7): 314\u201321. doi:10.1007\/s00011-007-7157-4. PMID\u00a018622687. S2CID\u00a025631088.  "},{"@context":"http:\/\/schema.org\/","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https:\/\/wiki.edu.vn\/en\/wiki24\/#breadcrumbitem","name":"Enzyklop\u00e4die"}},{"@type":"ListItem","position":2,"item":{"@id":"https:\/\/wiki.edu.vn\/en\/wiki24\/2015\/03\/02\/gw0742-wikipedia\/#breadcrumbitem","name":"GW0742 – Wikipedia"}}]}]